The funding supports development of an assay to detect and differentiate H5 influenza A from seasonal H1 and H3 subtypes, flu B, and COVID-19.

The funding supports development of an assay to detect and differentiate H5 influenza A from seasonal H1 and H3 subtypes, flu B, and COVID-19.

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

Bacteriologist and parasitologist Michelle Jakaitis uses a microscope to view a training sample of veligers, which are the ...

Avian influenza virus from the ongoing outbreak in dairy cattle appears to be keeping its bird-infecting features rather than ...

The HHS is betting $500 million on developing a universal flu vaccine that could protect against multiple flu strains.

A game shoot site in Somerset has been struck by avian influenza with about 2,500 nine-week-old pheasants affected. The ...

H5N1 avian influenza virus was first found infecting cattle in 2024, though its risk of adapting to infect and spread through ...

A government report recommended a series of actions including an on-farm vaccination trial in turkeys and exploring ...

Despite USDA issuing a conditional license for an avian flu vaccine for poultry and promising human vaccine trial results, Members stated: “You have advocated for these unproven approaches… ...

A report from the avian influenza vaccination task force, which looked at how best to manage highly pathogenic avian ...

Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose ...